Key facts
- Inquis Medical’s last known valuation is $375.0M (Jan 2026).
- It has raised $141.4M; the latest was Later Stage VC ($75.0M) in Jan 2026.
- Notable investors include ShangBay Capital, Marshall Wace, David Lamond, En Pointe, Junson Capital — 8 tracked in total.
- Status: Privately Held (backing).
Leadership
- Dan GeorgeChief Financial Officer
- Eric SteubenChief Operating Officer
- Matt FermanichExecutive Officer
- Mojgan SaadatChief Executive Officer & President
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Inquis Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for Inquis Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Inquis Medical
Developer of a peripheral thrombectomy medical device designed to address unmet clinical needs and improve the standard of care. The company's technology focuses on improving the management of venous thromboembolic diseases and also offers an efficient single-pass thrombectomy with minimal blood loss, enabling clients to have medical devices that address unmet needs with a long-lasting impact.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2020
- Employees
- 49
- Website
- inquismedical.com/
- Ownership
- Privately Held (backing)
Inquis Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inquis Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inquis Medical in its N-PORT filings yet. We sweep new filings monthly.